New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
07:03 EDTBDSI, ENDPBioDelivery Sciences announces Buprenorphine study to be locked by Endo Health
The database for the BEMA Buprenorphine Phase 3 clinical study in opioid naive patients with chronic pain is expected to be locked shortly by BDSI's partner, Endo Pharmaceuticals. This event is expected to trigger a $10M milestone payment from Endo per the licensing and development agreement signed in January 2012. In addition, based on recruitment rates in a second Phase 3 clinical study of BEMA Buprenorphine in an opioid experienced patient group, the database for this trial is anticipated to be locked by mid-2014, with results following shortly thereafter.
News For BDSI;ENDP From The Last 14 Days
Check below for free stories on BDSI;ENDP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 1, 2014
07:46 EDTENDPEndo price target raised to $84 from $75 at Stifel
Subscribe for More Information
July 29, 2014
10:05 EDTENDPEndo shares remain overvalued, says Cantor
Cantor Fitzgerald raised its priced target for Endo shares to $52 from $37 ahead of the company's Q2 results, but says the stock remains overvalued. The firm keeps a Sell rating on the name.
July 23, 2014
10:02 EDTENDPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTENDPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTENDPEndo initiated with a Buy at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use